Sponsor study identifier
Secondary identifiers
OTHER · SLMC CT-13008
observational
400
1 country
1
Study Start
December 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2014
Actual (reported)Study Completion
December 2014
Actual (reported)This study will identify significant clinical parameters and individual risk factors related to certain prostate disease (BPH, prostatitis and prostate cancer). With the identified important correlations, a locally generated bias free nomogram will be constructed for predicting prostate biopsy outcome among Asian men with indications for prostate biopsy. While this study will evaluate the accuracy and predictive value of this novel prostate disease nomogram.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2014
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2010
Date type not reportedThis date has not been verified as actual or estimated.
April 1, 2013
Actual (reported)April 8, 2013
Actual (reported)November 2014
Actual (reported)December 2014
Actual (reported)Incidence of prostate cancer (indolent vs aggressive type)
Incidence of new diagnosed prostate cancer among patients with indication presented for first TRUS prostate biopsy at stone and prostate treatment center.
1 year
Incidence of prostatitis (acute vs chronic)
Incidence of new diagnosed prostatitis among patients with indication presented for first TRUS prostate biopsy at stone and prostate treatment center.
1 year
Incidence of nodular hyperplasia (benign prostatic hyperplasia)
Incidence of new diagnosed nodular hyperplasia (benign prostatic hyperplasia) among patients with indication presented for first TRUS prostate biopsy at stone and prostate treatment center.
1 year
Incidence of patient with synchronous occurrence of prostate diseases (benign prostatic hyperplasia, prostatitis, prostate cancer)
1 year
Mean Age of patients with prostate cancer (PCA) or Prostatitis or BPH
1 year
Mean PSA value of patients with PCA, or Prostatitis or BPH
1 year
Mean BMI of patients with PCA, or Prostatitis or BPH
1 year
Patients diagnosed with Indolent type will be classified according to Epstein Criteria on histopathology results and National Comprehensive Cancer Network (NCCN) guideline recommended classification
Patients diagnosed with aggressive type will be classified according to Epstein criteria on final histopathology findings and NCCN guideline recommended classification
Patient diagnosed with Acute prostatitis- according to histopathology description of Biopsy result
Patient diagnosed with Chronic prostatitis- according to histopathology description of Biopsy result
Patient diagnosed with Benign Prostatic Nodular Hyperplasia- according to histopathology description of Biopsy result
This is a cross-sectional study prospectively collecting data from all patients who had their first Transrectal ultrasound (TRUS) prostate biopsy at the Stone and Prostate Treatment Center of St. Luke's Medical Center-Quezon City . Data will be collected uniformly for the purpose of building a clinical care prostate biopsy database. The indication for prostate biopsy is either a suspicious DRE findings or elevated PSA level (\>4.0ng/ml) or both.
Stone and Prostate Treatment Center- St. Luke's Medical Center, Philippines
Quezon City, National Capital Region, 1102, Philippines
Michael E. Chua, MD
St. Luke's Medical Center, Philippines
First Submitted
April 1, 2013
First Posted
April 8, 2013
Study Start
December 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2014
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
Contact the study team to confirm eligibility.
Study Completion
December 2014
Actual (reported)Last Updated
April 7, 2015
Record last verified: 2015-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: